金城医药（300233）8月25日主力资金净流出6716.91万元

Group 1 - The core viewpoint of the news highlights the financial performance and stock market activity of Jincheng Pharmaceutical as of August 25, 2025, with a closing price of 19.61 yuan, reflecting a 4.92% increase [1] - The company reported a total operating revenue of 1.36 billion yuan for the first half of 2025, representing a year-on-year decrease of 22.65% [1] - The net profit attributable to shareholders was 43.38 million yuan, down 66.78% year-on-year, while the non-recurring net profit was 38.73 million yuan, a decrease of 68.12% [1] Group 2 - Jincheng Pharmaceutical has a current ratio of 1.834, a quick ratio of 1.280, and a debt-to-asset ratio of 28.75% [1] - The company has made investments in 14 enterprises and participated in 15 bidding projects, with 36 trademark registrations and 68 patents [2] - The company was established in 2004 and is primarily engaged in the pharmaceutical manufacturing industry, with a registered capital of approximately 383.87 million yuan [1][2]